Role of physical exercise in Alzheimer's disease (Review)

WEI-WEI CHEN, XIA ZHANG and WEN-JUAN HUANG

Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China

Received January 7, 2016; Accepted February 22, 2016

DOI: 10.3892/br.2016.607

Abstract. The benefits of physical exercise on the brain and general wellness are well recognised, but not particularly well known to the general public. Understanding the importance of integrating active behavior for overall health is crucial at any age and particularly for the elderly who are at risk of developing Alzheimer's disease (AD), a disease mainly affecting individuals aged >65 years. AD is a neurodegenerative disease characterized by extracellular senile plaques of amyloid-β, intracellular neurofibrillary tangles of the protein tau, brain atrophy and dementia. The beneficial effects of physical exercise have been observed on the maintenance of brain size and efficiency for the prevention of AD risks, such as obesity, hypertension and stroke. These effects are extended to individuals with, or at risk of dementia and other age-related neurodegenerative disorders. Accordingly, although extensive studies are required to fully understand the mechanisms by which physical exercise procures beneficial effects, data suggest the relevance of integrating physical exercise in the prevention and/or cure of AD, disease whose incidence is predicted to increase in the future. Such an increase, may pose medical, social and economical challenges for populations and the health care system worldwide. In the present review we assess the positive aspects of physical exercise with regard to prevention and cure of AD.

Contents

1. Introduction
2. Alzheimer's disease
3. Beneficial effects of physical exercise on Alzheimer's disease
4. Conclusion

1. Introduction

Regular exercise including jogging, walking, biking, stretching, swimming and skipping may prevent and/or retard the progression of brain disorder and metabolic diseases such as obesity, diabetes and hypertension, which are risk factors of diseases affecting the brain (1). Regular physical exercise enhances the endurance of cells, tissues and organs to oxidative stress (2), increase energy metabolism (3), vascularization (4) as well as neurotrophin synthesis (5), all of which constitute important inducers of neurogenesis, muscle development, memory improvement and brain plasticity. These benefits are important in the prevention of Alzheimer's disease (AD) and provide treatment options for age-associated neurodegenerative disorders such as AD (6).

High-intensity training is more effective in women than in men after six months of training (7) and is associated with an increase in functional cognitive faculties, glucose metabolism, cardiorespiratory fitness and body composition (7). Furthermore, when the regular or high-intensity trainings are reinforced or replaced by resistance training or strength training (8), such as walking and moving around the house, climbing stairs, getting up from the floor and putting on socks daily or ≥2 days per week at a moderate intensity of ≥50% of one's maximum, there are long-term effects on brain health. For other causes of dementia, previous studies have reported an almost 37% reduction of the risk (9). These types of training particularly increase muscle mass in the human body and have beneficial effects on metabolic ageing (10). Loss of muscle mass has been identified in individuals at risk or diagnosed with AD (11,12). In concordance with the abovementioned data, a strong correlation between greater muscle strength and a low risk of developing dementia or AD in healthy individuals has been identified (13). Additionally, the abovementioned data suggest that practicing physical activity routinely throughout a subject's lifetime, at any age and especially for older adults, constitutes a strategy for increasing overall health and risks involved in the development of dementia and AD (9). Thus, engaging in such activity may reduce the wide range of individuals with neurological conditions. However, the benefits of exercise on brain health and wellness are poorly studied and the general public is unfamiliar with these benefits.

In this review, we evaluated aspects by which physical activity procures beneficial preventive or curative effects on AD and other age-associated neurodegenerative diseases.

2. Alzheimer's disease

Ageing is a risk factor of cognitive function impairment and dementia including AD, which is characterized by the
extracellular deposition of senile plaques of amyloid-β (Aβ), intracellular neurofibrillary tangles of protein tau, brain atrophy and dementia (14). Aβ-induced mitochondrial dysfunction has been associated with inhibition of the production of ATP (15-18) and the reduction of the activities of key enzymes of oxidative stress metabolism such as α-ketoglutarate dehydrogenase complex, pyruvate dehydrogenase complex and cytochrome oxidase. In addition, Aβ-induced reduced complex IV activity in mitochondria of the hippocampus and platelets (19) and the dysfunction of calcium homeostasis thereby increasing the accumulation of mitochondrial calcium that contribute to the decreased reuptake of calcium (20), leading to the translocation of pro-apoptotic molecules from mitochondria to cytosol and apoptosis, which results in increased activity of calmodulin-dependent kinase and calpain (17,21). Aβ-induced also increased the mutations of mitochondrial DNA (18,22).

Together with Aβ, intracellular neurofibrillary tangles favour the excessive accumulation of reactive oxygen species (ROS) due to mitochondrial dysfunction which increases oxidative stress (19) leading to increased levels of lipid peroxidation, protein oxidation and DNA/RNA oxidation (23) thereby causing neurodegeneration and cerebral amyloid angiopathy (CAA). ROS can also aggravate the production and aggregation of Aβ and promote the phosphorylation of tau, thus establishing a vicious cycle of pathogenesis in AD (15).

Another risk factor associated with ageing is the increase of small vascular diseases (SVD) (24), a set of pathophysiology involving subcortical lesions, microinfarction, lacunas and intracerebral small vessels including arteries, arterioles, capillaries and small veins (25). Specifically, unrelated to CAA, SVD is the most frequent vascular pathology in ageing in a healthy manner and AD brain. However, SVD alone or associated with AD has been considered as the major etiologic cause of morbidity, disability, and cognitive dysfunctions leading to dementia and mortality (26,27). Accordingly, several SVD, unrelated to atherosclerotic disease, are associated with inherited mutations (28) that result in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) (29,30). CARASIL is a single-gene encoding cell-signaling receptors instigating the degeneration of vascular smooth muscle in small arteries and arterioles, capillaries and small veins (25). Specifically, unrelated to CAA, SVD is the most frequent vascular pathology in ageing in a healthy manner and AD brain. However, SVD alone or associated with AD has been considered as the major etiologic cause of morbidity, disability, and cognitive dysfunctions leading to dementia and mortality (26,27).

Another risk factor associated with ageing is the increase of small vascular diseases (SVD) (24), a set of pathophysiology involving subcortical lesions, microinfarction, lacunas and intracerebral small vessels including arteries, arterioles, capillaries and small veins (25). Specifically, unrelated to CAA, SVD is the most frequent vascular pathology in ageing in a healthy manner and AD brain. However, SVD alone or associated with AD has been considered as the major etiologic cause of morbidity, disability, and cognitive dysfunctions leading to dementia and mortality (26,27). Accordingly, several SVD, unrelated to atherosclerotic disease, are associated with inherited mutations (28) that result in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) (29,30). CARASIL is a single-gene encoding cell-signaling receptors instigating the degeneration of vascular smooth muscle in small arteries and arterioles, caused by mutations in the HTRA1 gene encoding HtrA serine peptidase/protease 1 (29). Aberrant HTRA1 activity, results in increased transforming growth factor (TGF)-β1 signaling provoking multiple actions including vascular fibrosis and extracellular matrix (ECM) synthesis (29,30). TGF-β1 is increased in AD and is associated with the release of pro-inflammatory cytokines interleukin-1β and tumor necrosis factor-α, and results in the initiation and/or the propagation of a destructive inflammatory cycle in astroglial cells and neuronal apoptosis together with the development of vascular hypertrophy, fibrosis, and the accumulation of ECM components (31-35), which result in the decrease of brain perfusion and cerebral glucose metabolism. These reductions are also associated with the decrease in the neuronal expression of genes encoding subunits of the mitochondrial electron transporter chain (36).

3. Beneficial effects of physical exercise on Alzheimer's disease

Although there is a lack of consensus regarding optimal physical activities associated with AD prevention or improvement, aerobic activities (37-41) and balanced training of moderate-to-severe intensities are considered optimal (42). A meta-analysis suggested that although exercise has a positive effect on cognitive performance, cardiovascular fitness alone (VO2 Max) does not explain these benefits (43). However, the regular practice of walking improves cognition in AD (44,45), while strength training is particularly more effective for improving postural and motor function, and reducing the risk of developing AD (46), since it improves muscle mass and strength, shown to be affected in AD patients (10). In addition, environmental conditions such as bright light exposure and good nutrition may play an important role in improving training results (47,48).

Accordingly, the meta-analysis identified the preventive effects of physical activities against AD. The majority of longitudinal epidemiological studies have clearly shown associations between physical activities and the risk of cognitive decline in a dose-response manner (49,50), suggesting that physical activities may delay the onset of AD as well as the risk of cognitive decline (51-58) and mortality (59). The reduction of depression symptomatology (60-62), improvements in postural, motor functions (63,64) and the reduction of Aβ plaques as shown in a mouse model in which mice were required to run in the wheel have also been identified (65,66). The reduction of Aβ referred to neuroprotective mechanisms. Specifically, 40 min of physical activities such as the ergocycle, treadmill and stair-climbing activities over a period of 12 consecutive weeks, has been associated with an increase of cerebral blood flow that improves neurogenesis (67) in brain areas, including dentate gyrus of the hippocampus. The beneficial effects on cerebral blood flow have been associated with the reduction of cerebrovascular and endothelial dysfunction pathophysiology by improvement through the activation of nitric oxide (NO)/endothelial NO synthase (eNOS), resulting in the building of vascular reserve and the maintenance of neuronal plasticity (68). In addition, an aerobic program session lasting 3 weeks for 1 h for a period of 6 months increased the volume of gray and white matters in the cortical regions of subjects >60 years (69). Similar data however, were not identified in anaerobic conditions (69).

In concordance with those data, physical activity has been found to counteract the noxious effects of oxidative stress in animal models in which the reduction of oxidative stress was also associated with the reduction of cholesterol and insulin resistance, resulting in increasing vascularization and improving energy metabolism such as glucose metabolism (40,68,70-72) and facilitating neurogenesis and synaptogenesis, which improve memory and cognitive functions (40,55,67,68,70,72). Accordingly, in old mouse models of AD trained with sedentary control mice, the hippocampal neurogenesis was associated with synaptogenesis and spatial memory improvements (71,73). Similarly, increases of the volume of hippocampus of >2% together with plasma concentration of brain-derived neurotrophic factor (BDNF) were also observed in older healthy subjects (74) and in individuals with AD (75) following one year of moderately intense
aerobic exercise (3 days per week, 40 min per session). The increase in BDNF can be enhanced by the environmental condition. In mice trained in an enriched environment, cognitive improvements related to benefits from environmental enrichment were higher in BDNF, hippocampal neurotrophin and activation of hippocampal neurogenesis than those of mice in the same training program in poor environmental enrichment (66). Additionally, physical training was associated with the decrease of neurofibrillary degeneration and neuroinflammation as well as in the prevention against loss of the expression of choline acetyltransferase which is affected in mouse models of AD after 9 months of training (76,77). Of note, neurotrophins are proteins classically identified as mediators of neuronal survival and differentiation during development. They also maintain viability of neurons in adulthood, protecting, restoring neurons in response to injury and ageing. The efficacy of synaptic transmission is adaptable and neurotrophins serve as activity-dependent modulators of synaptic plasticity (78) in which BDNF has emerged as a key mediator in the memory centers of the brain (79). Notably, neurotrophins regulate target genes encoding structural proteins, enzymes or neurotransmitters resulting in the modification of neuronal morphology and function. These data are appropriate for prescription of physical activity for brain health although further investigations are required to identify reasonable standards and universal prevents and/or curative protocols for AD and related dementia.

4. Conclusion

Aerobic multicomponent training involving power and balance exercises induces important beneficial effects on health thereby improving the executive function, attentional capacity, processing speed, episodic memory and procedural memory (80‑82). Moderate and high intensities have demonstrated a neuroprotective effect through the production of antioxidant enzymes and growth factors such as superoxide dismutase, eNOS, BDNF, nerve growth factors, insulin-like growth factors and vascular endothelial growth factor and by reducing the production of ROS, neuroinflammation, the concentration of Aβ plaques in cognitive regions and tau pathology, leading to the improvement of cerebral blood flow, hyperemia, cerebrovascular reactivity and memory (68,70,83). Although extensive studies are required to understand mechanisms by which physical exercise procures beneficial effects to establish standard protocols, the practice of physical activity may be disregarded by a large number of people, particularly those at risk or suffering AD, or taking medication.

References

1. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTierman A, Plymate SR, Fishe MA, Watson GS, Cholerton BA, et al: Effects of aerobic exercise on mild cognitive impairment: A controlled trial. Arch Neurol 67: 71‑79, 2010.
2. Radak Z, Zhao Z, Koltai E, Ohno H and Atalay MA: Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS‑dependent adaptive signaling. Antioxid Redox Signal 18: 1208‑1246, 2013.
3. van Praag H, Flesher M, Schwartz MW and Mattson MP: Exercise, energy intake, glucose homeostasis, and the brain. J Neurosci 34: 15139‑15149, 2014.
4. Gertz K, Priller J, Kronenberg G, Fink KB, Winter B, Schröck H, Ji S, Milosevic M, Harms C, Böm H, et al: Physical activity improves long‑term stroke outcome via endothelial nitric oxide synthase‑dependent augmentation of neurovascularization and cerebral blood flow. Circ Res 99: 1132‑1140, 2006.
5. Zoladz JA and Pilk A: The effect of physical activity on the brain derived neurotrophic factor: From animal to human studies. J Physiol Pharmacol 61: 533‑541, 2010.
6. Garthit M, Costa JLR, Hernández SSS, Vital TM, Stein AM, dos Santos JG and Stella F: Effects of resistance training on the performance of activities of daily living in patients with Alzheimer's disease. Geriatr Gerontol Int 13: 322‑328, 2013.
7. Bow C, Cheung C, Gao Y, Xiao S, Lau K, Soong C, Yeung S and Kung A: Bone mineral density and serum osteoprotogerin levels in pre‑and post‑menopausal women. Hong Kong Med J 17: 9, 2011.
8. American College of Sports Medicine: American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. Med Sci Sports Exerc 41: 687‑708, 2009.
9. Laurin D, Verruealt R, Lindsay J, MacPherson K and Rockwood K: Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 58: 498‑504, 2001.
10. Hurley BF, Hanson ED and Sheaff AK: Strength training as a countermeasure to aging muscle and chronic disease. Sports Med 41: 289‑306, 2011.
11. Burns JM, Johnson DK, Watts A, Swedlow RH and Brooks WM: Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol 67: 428‑433, 2010.
12. Boyle PA, Buchman AS, Wilson RS, Leurgans SE and Bennett DA: Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community‑dwelling older persons. Arch Neurol 66: 1339‑1344, 2009.
13. Taafe DR, Irie F, Masaki KH, Abbott RD, Petrovitch H, Ross GW and White LR: Physical activity, physical function, and incident dementia in elderly men: The Honolulu‑Asia Aging Study. J Gerontol A Biol Sci Med Sci 63: 529‑535, 2008.
14. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger‑Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, et al: Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9: 1118‑1127, 2010.
15. Zhao Y and Zhao B: Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013: 316523, 2013.
16. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G and Smith MA: Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 80: 195‑200, 2010.
17. Zhang C, Rissmann RA and Feng J: Characterization of ATP alternations in an Alzheimer's disease transgenic mouse model. J Alzheimers Dis 44: 375‑378, 2015.
18. Kwiatkowski D, Czarny P, Galecki P, Bachurska A, Talarowska M, Orzechowska A, Bobińska K, Bielecka‑Kowalska A, Pietras T, Szczeniaw J, et al: Variants of base excision repair genes MUTYH, PARP1 and XRCCL1 in Alzheimer's disease risk. Neupyscobiology 71: 176‑186, 2015.
19. Gandhi S and Abramov AY: Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012: 428010, 2012.
20. Ito E, Oka K, Etcheberrygaray R, Nelson TJ, McPhie DL, Tofel‑Grehl B, Gibson GE and Alkon DL: Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA 91: 534‑538, 1994.
21. da Silva Oliveira GL and de Freitas RM: Potential involvement of oxidative stress in induction of neurodegenerative diseases: Actions, mechanisms and neurotherapeutic potential of natural antioxidants. Afr J Pharm Pharmacol 8: 685‑700, 2014.
22. Gerenu G, Liu K, Chojnacki JE, Saathoff JM, Martínez‑Martín P, Perry G, Zhu X, Lee HG and Zhang S: Curcumin/melatonin hybrid 5‑[4‑hydroxy‑phenyl‑]‑3‑oxo‑pentoic acid [2‑(5‑methox y‑1H‑indol‑3‑yl)‑ethy]‑amide ameliorates AD‑like pathology in the APP/PS1 mouse model. ACS Chem Neurosci 6: 1393‑1399, 2015.
23. Butterfield DA, Drake J, Pocernich C and Castegna A: Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid β‑peptide. Trends Mol Med 7: 548‑554, 2001.
24. Chamorro A, Pujoj J, Saiz A, Vila N, Vilanova JC, Alday M and Blanc R: Periventricular white matter lucencies in patients with lacunar stroke. A marker of too high or too low blood pressure? Arch Neurol 54: 1284‑1288, 1997.
25. Antoni L: Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9: 689‑701, 2010.
26. Aguerro-Torres H, Kivipelto M and von Strauss E: Rethinking the dementia diagnoses in a population-based study: What is Alzheimer’s disease and what is vascular dementia? A study from the kihnu omen project. Dement Geriatr Cogn Disord 22: 244-249, 2006.

27. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P and Polvikoski T: Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 226: 75-80, 2004.

28. Matrux S: Contribution to the differential histological study of dementia senilis & Alzheimer’s disease. Psychiatria Neurologica (Basel) 136: 146-156, 1958 (In French).

29. Yamamoto Y, Crags L, Baumann M, Kalimo H and Kalaria RN: Review: Molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol Appl Neurobiol 37: 121-131, 2011.

30. Tikk S, Baumann M, Sitonen M, Pasanen P, Pöyhönen M, Myllykangas L, Viitanen M, Fukutake T, Cognat E, Joutel A, et al.: CADASIL and CARASIL. Brain Pathol 24: 525-544, 2014.

31. Kalaria RN and Pax AB: Increased collagen content of cerebral microvessels in Alzheimer’s disease. Brain Res 785: 349-352, 1995.

32. Schultz JJ, Witt SA, Glascock BJ, Niemlan ML, Reiser PJ, Nix SL, Kimball TR and Doetschman T: TGF-beta mediates the hypertrophic cardiomyocyte growth during induced angiogenesis II. Clin Invest 109: 1987-1990, 2002.

33. Rosenkranz S: TGF-beta and angiogenes in cardiac remodeling. Cardiovasc Res 63: 423-432, 2004.

34. Yurovsky VV, Gerzanich V, Ivanova S, Dong Y, Tsumbayoku Y and Simard JM: Autocrine TGF-beta mediates angiogenesis in diabetic retinopathy. Am J Pathol 170: 996-1006, 2007.

35. Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G and Egido J: TGF-β signaling in vascular fibrosis. Cardiovasc Res 74: 196-206, 2007.

36. Liaw WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, Niedzielko TL, Schneider LE, Mastrandecin D, Caselli R, et al.: Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurones. Proc Natl Acad Sci USA 105: 4441-4446, 2008.

37. Yu F and Swartwood RM: Feasibility and perception of the impact from aerobic exercise in older adults with Alzheimer’s disease. Am J Alzheimers Dis Other Dem 26: 381-388, 2011.

38. Venturelli M, Scarsini R and Schena F: Six-month walking fitness and cognitive performance. Brain Res Brain Res Rev 52: 107-119, 2006.

39. Archer T: Physical exercise alleviates debilities of normal aging and Alzheimer’s disease. Acta Neurol Scand 96: 105-113, 1997.

40. Paulozzi LJ, Wadsworth H, Siegel D, Hanlon J, Bower K, Xie X and Jones J: Efforts to protocol a randomized trial. BMC Geriatr 9: 29, 2009.

41. Widdicombe J, Tappin DM and Silibey BA: A meta-regression to examine the relationship between aerobic fitness and cognitive performance. Brain Res Brain Res Rev 52: 381-388, 2006.

42. Venturelli M, Scarsini R and Schena F: A community-based approach to trials of aerobic exercise in aging and Alzheimer’s disease. Contemp Clin Trials 33: 1035-1042, 2012.

43. Yu F and Swartwood RM: TGF-beta1 and angiotensin receptor signaling. Am J Hypertens 23: 10-16, 2010.

44. McCurry SM, Pike KC, Vitelli MV, Logsdon RG, Larson EB and Teri L: Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer’s dementia: Results of a randomized, controlled trial. J Am Geriatr Soc 59: 1393-1402, 2011.

45. Abe K: Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 79: 1071-1071; author reply 1071, 2012.

46. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS and Bennett DA: Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 78: 1323-1329, 2012.

47. Norton S, Matthews FE, Barnes DE, Yaffe K and Brayne C: Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neuroc 13: 788-794, 2014.

48. Pitkälä KH, Pöysti MM, Laakkonen ML, Tilvis RS, Savikko N, Kautiainen H and Strandberg TE: Effects of the Finnish Alzheimer disease exercise trial (FAMEX): A randomized controlled trial. JAMA Intern Med 173: 894-901, 2013.

49. Hamer M and Chida Y: Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. Psychol Med 39: 3-11, 2009.

50. Um HS, Kang EB, Koo JH, Kim HT, Jin-Lee, Kim EJ, Yang CH, An GY, Cho IH and Cho JY: Treadmill exercise reduces neuronal cell death in an aged transgenic mouse model of Alzheimer’s disease. Neurosci Res 69: 161-173, 2011.

51. Yu F, Kolanowski AM, Strumpf NE and Eslinger PJ: Improving cognition and function through exercise intervention in Alzheimer’s disease. J Nurs Scholarsh 38: 358-365, 2006.

52. Holliday Y, Pillar V, Serassenzak A, Reynolds F, Thomas D, Andreu S, Rivièrè D and Vellas B: Exercise program for nursing home residents with Alzheimer’s disease: A 1-year randomized, controlled trial. J Am Geriatr Soc 55: 158-165, 2007.

53. Buschert V, Bokde AL and Hampel H: Cognitive intervention in Alzheimer’s disease. Nat Rev Neurol 6: 508-517, 2010.

54. Cendoroglo MS, Thiesen EJ, Blake CM, Forbes SS and Forbes S: Exercise programs for people with dementia. Sao Paulo Med J 132: 195-196, 2014.

55. Scarneas N, Luchingsja AR, Brickman AM, Cosentino S, Schupf N, Xin-Tang M, Gu Y and Stern Y: Physical activity and Alzheimer disease course. Am J Geriatr Psychiatry 19: 471-481, 2011.

56. Regan C, Katona C, Walker Z and Livingston G: Relationship of exercise and other risk factors to depression of Alzheimer’s disease: The LASER-AD study. Int J Geriatr Psychiatry 20: 261-268, 2005.

57. de Andrade LP, Gobbi LT, Coelho FG, Gobbi S and Stella F: Benefits of multimodal exercise intervention for postural control and frontal cognitive functions in individuals with Alzheimer’s disease: A controlled trial. J Am Geriatr Soc 61: 1919-1926, 2013.

58. Yuehe CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, Timson BF and Csernansky JG: Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer’s disease. Neurobiol Dis 35: 426-432, 2009.

59. Woll SA, Kronenberg G, Lehmkan A, Overall R, Staufenbuel M and Kempermann G: Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer’s disease. Biochem Biophys Acta 1764: 2010.

60. Pereira AC, Huddleston DE, Brickman AM, Sosunov AA, Her D, McKhann GM, Sloan R, Gage FH, Brown TR and Small SA: An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci USA 102: 5638-5643, 2007.

61. Lange-Åssenfeldt C and Kojda G: Alzheimer’s disease, cerebrovascular dysfunction and the benefits of exercise: From vessels to neurons. Exp Gerontol 43: 499-504, 2008.
69. Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E, Elavsky S, Marquez DX, Hu L and Kramer AF: Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci 61: 1166-1170, 2006.

70. Radak Z, Hart N, Sarga L, Koltai E, Atalay M, Ohno H and Boldogh I: Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis 20: 777-783, 2010.

71. Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, Hwang DY and Cho JY: Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol Med 22: 529-539, 2008.

72. Pérez CA and Cancela Carral JM: Benefits of physical exercise for older adults with Alzheimer's disease. Geriatr Nurs 29: 384-391, 2008.

73. van Praag H, Christie BR, Sejnowski TJ and Gage FH: Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA 96: 13427-13431, 1999.

74. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, et al: Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA 108: 3017-3022, 2011.

75. Coelho FG, Vital TM, Stein AM, Arantes FJ, Rueda AV, Camarini R, Teodorov E and Santos-Galduróz RF: Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer's disease. J Alzheimers Dis 39: 401-408, 2014.

76. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M, Sultan A, Troquier L, Leboucher A, Cailleriez R, et al: Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis 43: 486-494, 2011.

77. Leem YH, Lee YI, Son HJ and Lee SH: Chronic exercise ameliorates the neuroinflammation in mice carrying NSE/htau23. Biochem Biophys Res Commun 406: 359-365, 2011.

78. Schinder AF and Poo M: The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 23: 639-645, 2000.

79. Gottschalk WA, Jiang H, Tartaglia N, Feng L, Figurov A and Lu B: Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus. Learn Mem 6: 243-256, 1999.

80. Colcombe S and Kramer AF: Fitness effects on the cognitive function of older adults: A meta-analytic study. Psychol Sci 14: 125-130, 2003.

81. Angevaren M, Aufdemkampe G, Verhaar H, Aleman A and Vanhees L: Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev 3: CD005381, 2008.

82. Smith PJ, Blumenthal JA, Hoffman BM, Cooper H, Strauman TA, Welsh-Bohmer K, Browndyke JN and Sherwood A: Aerobic exercise and neurocognitive performance: A meta-analytic review of randomized controlled trials. Psychosom Med 72: 239-252, 2010.

83. Vaynman S, Ying Z and Gomez-Pinilla F: Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci 20: 2580-2590, 2004.